Web Watch
Web Watch in One Page
The five live watch items update the variables the long-term thesis rests on, not the next quarterly print. Two follow the load-bearing wide-moat metrics — institutional U.S. Treasury electronic share through the Treasury clearing rollout, and any sign Bloomberg or CME's CMESC offering breaks into TW's flagship rates franchises. One follows the near-term debate that controls the multiple — cash credit fee per million, plus competitive share with MarketAxess and Trumid. One follows the management variable — whether the $500M February 2026 buyback authorization translates into per-share value creation against the LSEG-controlled cap table. One follows the second engine the bears are not pricing — international growth (EU govies, swaps, EM) and the $785M ICD corporate-treasurer cross-sell. Together they cover the four drivers and four failure modes that decide whether this is a high-teens compounder for another decade or a normalizing platform on its way to mid-single-digit growth.
Active Monitors
| Rank | Watch item | Cadence | Why it matters | What would be detected |
|---|---|---|---|---|
| 1 | Institutional UST share + Treasury clearing rollout | Daily | The single load-bearing wide-moat variable in the long-term thesis (Driver #2). Rates is 56% of revenue and the CME-band peer multiple only stands if institutional UST electronic share holds 50% through the clearing cycle. The 2025 reframing of the disclosure from "above 50%" to "above 50% vs. main electronic competitor" was the most concerning signal in the entire report. | Any new Tradeweb disclosure of institutional UST electronic share or further reframing of the metric; dealer panel composition changes; FICC vs. CMESC volume routing decisions; Treasury Department / SEC implementation updates around the Dec 31 2026 cash and Jun 30 2027 repo compliance deadlines. |
| 2 | Bloomberg + CME/CMESC competitive moves in flagship rates | Daily | The asymmetric tail in the failure-mode table. Bloomberg has been passive in rates for 25 years; a single material market-structure move by Bloomberg in U.S. Treasuries or institutional swaps would re-rate the franchise from wide-moat compounder to contested platform within one or two quarters. CMESC bundling clearing with BrokerTec execution is the explicit mechanism the bear case names. | A Bloomberg multi-year market-structure investment, new pricing strategy, or aggressive sales push in flagship rates; CMESC launch, dealer-adoption, or volume-share milestones; bundling of CME clearing with BrokerTec execution; new dealer SEF/SBSEF/MTF registrations; analyst calls flagging a strategic posture shift by any of these venues. |
| 3 | Credit franchise pricing + MarketAxess/Trumid share | Daily | Cash credit fee per million fell -14.7% YoY in Q1 FY26 — the explicit TD Cowen downgrade thesis. Two more prints decide whether this is dealer-plan reclassification plus retail mix-out (transient and bullish underneath) or structural price erosion (durable and value-destructive). MarketAxess's own 10-K disclosure of share losses to Tradeweb is the cleanest moat evidence in the entire file. | Quarterly cash credit fee per million prints and any CFO decomposition; U.S. IG/HY/munis TRACE share trajectory; MarketAxess quarterly or 10-K share-table disclosures; Trumid ADV announcements or BlackRock-backed funding rounds; minimum-fee-floor or fixed-vs-variable plan changes; broker downgrades or upgrades that explicitly cite the fee/MM line. |
| 4 | Capital allocation discipline + LSEG control overhang | Weekly | The management variable in the long-term thesis (Durability Test #5). The $2B net cash position has accumulated since IPO and $104M of FY25 buybacks only offset $104M of SBC. The $500M February 2026 authorization is the first credible signal of a regime change. LSEG voting control (89.9%) and the $336M Tax Receivable Agreement are structural overhangs that would only unwind through a stake reduction or TRA payoff. | Quarterly buyback execution pace vs. the ~$85M SBC tax withholding run-rate; new buyback authorizations; dividend changes; M&A announcements (size, target, multiple, platform fit); LSEG voting-stake reductions or secondary offerings; TRA payoff activity; charter amendments affecting the four-class share structure; amendments to the Tradeweb-LSEG market-data license. |
| 5 | International franchise + ICD corporate cross-sell | Daily | International is 44% of revenue and ~60% of Q1 FY26 growth, compounding at ~25% per management — yet sell-side models still slot it as "rest of revenue." If international holds 20%+ for two more years the consolidated 15% organic-growth narrative is defended and the bull case lives. The $785M ICD acquisition is the cleanest test of reinvestment discipline (Driver #5); Q4 FY26 is the practical deadline to show the deal delivers. | Monthly EU govies and global swaps ADV growth; Asia/Pacific and EM rates volume disclosures; investor-conference commentary on international compounding; EU MiFID II/III and post-Brexit market-structure rulings; ICD platform money-markets ADV and corporate-treasurer T-bill cross-sell traction; Yieldbroker and r8fin integration milestones; FX-related guidance changes. |
Why These Five
The report's most important open questions are concentrated in four places: (a) does the rates moat survive the Treasury clearing cycle and Bloomberg's continued passivity, (b) does the credit franchise stabilize or reprice structurally, (c) does management decouple buybacks from SBC and turn the cash flywheel into per-share value creation against the LSEG voting overhang, and (d) does the international/ICD engine the bears do not price hold its 25% compounding pace. Monitors 1 and 2 cover (a) — the two halves of the wide-moat rating in rates. Monitor 3 covers (b) — the near-term gating debate that controls the multiple, paired with the bilateral share-transfer evidence from the named competitor's own filings. Monitor 4 covers (c) — the only management-controlled variable in the durability tests. Monitor 5 covers (d) — the second engine and the cross-sell test of the $785M ICD deal. Together they map directly onto every High-confidence driver, every Critical and High failure mode, and the two near-term resolution signals the report names as actionable.